Indication
Small Cell Lung Cancer (SCLC), Extensive Stage
6 clinical trials
8 products
1 drug
Clinical trial
A Phase Ib/II Clinical Study of Anti-PD-1 and CTLA-4 Bispecific Antibody, Cadonilimab(AK104), in Combination With Chiauranib in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Who Failed First-line Platinum-based Chemotherapy in Combination With Programmed Cell Death-1(PD1)/Programmed Cell Death Protein Ligand-1(PDL1) InhibitorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
AK104Product
RYZ101Clinical trial
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)Status: Recruiting, Estimated PCD: 2024-04-01
Product
AtezolizumabProduct
EtoposideProduct
CarboplatinClinical trial
Phase 2 Trial of Translational Approach to First Line cHemoimmunotherapy Followed by Maintenance With pembrOlizumab and Olaparib in Extensive-Stage Small-Cell Lung CanceR.Status: Recruiting, Estimated PCD: 2026-08-01
Product
Pembrolizumab/OlaparibClinical trial
A Single-arm Phase II Trial of the Addition of Niraparib to Anti-PD-L1 Antibody Maintenance in Patients With SLFN11-positive, Extensive-disease Small Cell Lung Cancer.Status: Recruiting, Estimated PCD: 2025-05-01
Product
NiraparibClinical trial
Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical SignificanceStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive StageStatus: Not yet recruiting, Estimated PCD: 2025-02-25
Drug
Adebrelimab